Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Sell
24
CLBT Quote, Financials, Valuation and Earnings
Last price:
$19.89
Seasonality move
:
-0.89%
Day range:
$18.73 - $19.29
52-week range:
$10.25 - $26.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.04x
P/B ratio:
13.70x
Volume:
943.2K
Avg. volume:
2.2M
1-year change:
64.64%
Market cap:
$4.6B
Revenue:
$401.2M
EPS (TTM):
-$1.39
Analysts' Opinion
-
Consensus RatingCellebrite DI has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $28.00, Cellebrite DI has an estimated upside of 45.61% from its current price of $19.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.00 representing 100% downside risk from its current price of $19.23.
Fair Value
-
According to the consensus of 6 analysts, Cellebrite DI has 45.61% upside to fair value with a price target of $28.00 per share.
CLBT vs. S&P 500
-
Over the past 5 trading days, Cellebrite DI has overperformed the S&P 500 by 4.84% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cellebrite DI does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cellebrite DI has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Cellebrite DI reported revenues of $109M.
Earnings Growth
-
Cellebrite DI earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cellebrite DI reported earnings per share of $0.08.
Enterprise value:
4.2B
EV / Invested capital:
12.37x
Price / LTM sales:
10.04x
EV / EBIT:
--
EV / Revenue:
10.36x
PEG ratio (5yr expected):
-0.06x
EV / Free cash flow:
34.20x
Price / Operating cash flow:
33.13x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$338.6M
Return On Assets:
-48.16%
Net Income Margin (TTM):
-70.54%
Return On Equity:
-235.18%
Return On Invested Capital:
-235.18%
Operating Margin:
14.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $270.7M | $325.1M | $401.2M | $93M | $109M | |
| Gross Profit | $219.9M | $271.9M | $338.6M | $78.1M | $91.4M | |
| Operating Income | $1M | $33.2M | $56.9M | $15M | $15.7M | |
| EBITDA | $10.2M | $43.2M | -$45.5M | $17.6M | $18.5M | |
| Diluted EPS | $0.61 | -$0.43 | -$1.39 | -$0.08 | $0.08 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $324.3M | $273.2M | $295.9M | $422.1M | $567.6M | |
| Total Assets | $364.4M | $339.8M | $403.3M | $532.9M | $690.6M | |
| Current Liabilities | $159.4M | $186.6M | $207.8M | $253.8M | $295.5M | |
| Total Liabilities | $300.6M | $413.1M | $329.4M | $498.7M | $354.5M | |
| Total Equity | $63.8M | -$73.3M | $73.9M | $34.2M | $336M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $20.6M | $102.1M | $132.2M | $43.8M | $66M | |
| Cash From Investing | -$91.2M | -$22.5M | -$149.5M | $3.2M | -$15.9M | |
| Cash From Financing | $14M | $21.8M | $20.7M | $4.5M | $6.7M | |
| Free Cash Flow | $11.5M | $94.1M | $121.6M | $38.9M | $61.7M | |
CLBT
Sector
Market Cap
$4.6B
$88.2M
Price % of 52-Week High
73.12%
60.35%
Dividend Yield
0%
0%
Shareholder Yield
--
0.83%
1-Year Price Total Return
64.64%
-16.67%
Beta (5-Year)
--
0.910
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$18.46
200-day SMA
Buy
Level
$17.60
Bollinger Bands (100)
Sell
Level
18.25 - 22.87
Chaikin Money Flow
Buy
Level
1.3M
20-day SMA
Buy
Level
$18.36
Relative Strength Index (RSI14)
Buy
Level
50.02
ADX Line
Buy
Level
7.14
Williams %R
Sell
Level
-1.9231
50-day SMA
Sell
Level
$21.29
MACD (12, 26)
Buy
Level
2.71
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
1.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.7349)
Sell
CA Score
(Annual)
Level (-0.6947)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.4676)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.
Stock Forecast FAQ
In the current month, CLBT has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLBT average analyst price target in the past 3 months is $28.00.
-
Where Will Cellebrite DI Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cellebrite DI share price will rise to $28.00 per share over the next 12 months.
-
What Do Analysts Say About Cellebrite DI?
Analysts are divided on their view about Cellebrite DI share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cellebrite DI is a Sell and believe this share price will drop from its current level to $26.00.
-
What Is Cellebrite DI's Price Target?
The price target for Cellebrite DI over the next 1-year time period is forecast to be $28.00 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLBT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cellebrite DI is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CLBT?
You can purchase shares of Cellebrite DI via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cellebrite DI shares.
-
What Is The Cellebrite DI Share Price Today?
Cellebrite DI was last trading at $19.89 per share. This represents the most recent stock quote for Cellebrite DI. Yesterday, Cellebrite DI closed at $19.23 per share.
-
How To Buy Cellebrite DI Stock Online?
In order to purchase Cellebrite DI stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did StoneCo Stock Go Up So Much?
Brazilian fintech company StoneCo (NASDAQ:STNE) has been on a tear…
Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 24
Regencell Bioscience Holdings [RGC] is down 28.36% over the past day.
Buy
54
TNXP alert for Mar 24
Tonix Pharmaceuticals Holding [TNXP] is up 32.39% over the past day.
Sell
36
VMI alert for Mar 24
Valmont Industries [VMI] is up 4.67% over the past day.
